查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433619

寡核苷酸合成的全球市場規模、佔有率和趨勢分析報告：按產品/服務、應用、地區和細分市場預測（2024-2030）

Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, PCR Assays & Panels), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 135 Pages | 商品交期: 2-10個工作天內

價格

寡核苷酸合成市場成長與趨勢：

預計2030年，全球寡核苷酸合成市場規模將達85.3億美元，2024年至2030年複合年成長率為13.21%。臨床試驗中強大的寡核苷酸療法管道、基因編輯技術的進步以及生物技術公司不斷增加的研發支出是推動市場成長的一些關鍵因素。

參與的寡核苷酸療法正處於後期臨床試驗中，預計將在預測期內核准和商業化。公司正在增加投資以開發基於寡核苷酸的療法。 2023年10月，GSK plc和Arrowhead Pharmaceuticals與強生旗下楊森製藥公司（Janssen）達成協議，獲得JNJ-3989的全球獨家開發和商業化權利。宣布簽署協議，將該公司轉讓給GSK 。楊森最初於 2018 年從 Arrowhead 引入了 JNJ-3989（以前稱為 ARO-HBV）。成熟製藥公司的類似舉措預計將在預測期內推動市場成長。

政府機構，例如負責實驗室的醫療補助和醫療保險服務中心、負責行銷的聯邦貿易委員會以及負責套件和資訊的FDA，確保基因組學和基因檢測的安全、適當和準確，並在成功中發揮著關鍵作用基因體學。美國國立衛生研究院和威康信託基金等國際資助機構也正在資助基因研究，預計將重振已開發經濟體和新興經濟體的基因組研究。

2021 年 5 月，英國政府宣佈為基因組學研究和資料驅動計畫提供 4,340 萬美元（3,700 萬舉措）資助，並於 2019 年 9 月啟動了英國功能基因組計畫和英國基因組實施計畫。 Genomics UK 策略將在 Genomics England計劃的幫助下實施，該計畫將獲得 1,990 萬美元（1,700 萬英鎊）來研究新生兒定序的潛在價值。

寡核苷酸合成市場報告亮點：

  • 按產品/服務分類，服務業在市場中佔據主導地位，2023 年佔有率將超過 37.0%。
  • 按應用分，PCR引子細分市場在2023年佔據最大市場佔有率。它們在放大特定 DNA 或 RNA 序列方面發揮著至關重要的作用，使其成為該市場的重要組成部分。
  • 由於主要企業的增加、各種應用中對合成 DNA 和 RNA 序列的需求不斷增加以及有利的監管環境等因素，北美主導了市場。
  • 2023年5月，金斯瑞將擴建位於中國江蘇省鎮江市的生命科學設施，為研發和臨床前應用提供快速、高純度的寡核苷酸和胜肽合成服務。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章寡核苷酸合成市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 業務分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章寡核苷酸合成市場：產品與服務的估算與趨勢分析

  • 產品和服務的市場佔有率（2023/2030）
  • 市場規模、預測、趨勢分析（2018-2030）

第5章寡核苷酸合成市場：應用預估及趨勢分析

  • 應用市場佔有率（2023/2030）
  • 市場規模、預測、趨勢分析（2018-2030）

第6章寡核苷酸合成市場：區域估計與趨勢分析

  • 區域市場佔有率分析（2023/2030）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 公司/競爭對手分類
  • 策略規劃
  • 企業市場分析（2023）
  • 公司簡介/名單
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • Kaneka Eurogentec SA
    • LGC Biosearch Technologies
    • Biolegio
    • Twist Bioscience
Product Code: GVR-2-68038-593-9

Oligonucleotide Synthesis Market Growth & Trends:

The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.

Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.

In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.

Oligonucleotide Synthesis Market Report Highlights:

  • Based on product & services, the service segment dominated the market with more than 37.0% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
  • Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
  • North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
  • In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product & service
    • 1.2.2. Application
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide Synthesis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
      • 3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.4. Increased public-private spending on genomics
      • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
      • 3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
  • 3.3. Business Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis

  • 4.1. Product & Service Market Share, 2023 & 2030
  • 4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.2.1. Oligonucleotides
      • 4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2. DNA
      • 4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.2. Column-based
      • 4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.3. Array-based
      • 4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3. RNA
      • 4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2. By Technology
      • 4.2.1.3.2.1. Column-based
      • 4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2.2. Array-based
      • 4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3. By Type
      • 4.2.1.3.3.1. Short RNA Oligos (<65 nt)
      • 4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.2. Long RNA Oligos (>65 nt)
      • 4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.3. CRISPR (sgRNA)
      • 4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.2. Equipment/Synthesizer
      • 4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.3. Reagents
      • 4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.4. Services
      • 4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2. DNA
      • 4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2. Custom oligo synthesis services
      • 4.2.4.2.2.1. 25 nmol
      • 4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.2. 50 nmol
      • 4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.3. 200 nmol
      • 4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.4. 1000 nmol
      • 4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.5. 10000 nmol
      • 4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.3. Modification services
      • 4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.4. Purification services
      • 4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3. RNA
      • 4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2. Custom oligo synthesis services
      • 4.2.4.3.2.1. 25 nmol
      • 4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.2. 100 nmol
      • 4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.3. 1000 nmol
      • 4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.4. 10000 nmol
      • 4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.3. Modification services
      • 4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.4. Purification services
      • 4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.2.1. PCR primers
      • 5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2. Academic research institutes
      • 5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.2. Diagnostic laboratories
      • 5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.3. Pharmaceutical - biotechnology companies
      • 5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2. PCR assays and panels
      • 5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2. Academic research institutes
      • 5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.2. Diagnostic laboratories
      • 5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.3. Pharmaceutical - biotechnology companies
      • 5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3. Sequencing
      • 5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2. Academic research institutes
      • 5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.2. Diagnostic laboratories
      • 5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.3. Pharmaceutical - biotechnology companies
      • 5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.4. DNA microarrays
      • 5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2. Academic research institutes
      • 5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.2. Diagnostic laboratories
      • 5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.3. Pharmaceutical - biotechnology companies
      • 5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.5. Fluorescence in situ hybridization (FISH)
      • 5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2. Academic research institutes
      • 5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.2. Diagnostic laboratories
      • 5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.3. Pharmaceutical - biotechnology companies
      • 5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.6. Antisense oligonucleotides
      • 5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2. Academic research institutes
      • 5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.2. Diagnostic laboratories
      • 5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.3. Pharmaceutical - biotechnology companies
      • 5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.7. Other applications
      • 5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. Key country dynamics
      • 6.2.1.2. Regulatory framework
      • 6.2.1.3. Competitive scenario
      • 6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.2.2. Canada
      • 6.2.2.1. Key country dynamics
      • 6.2.2.2. Regulatory framework
      • 6.2.2.3. Competitive scenario
      • 6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. UK
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. France
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Italy
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Regulatory framework
      • 6.3.4.3. Competitive scenario
      • 6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Spain
      • 6.3.5.1. Key country dynamics
      • 6.3.5.2. Regulatory framework
      • 6.3.5.3. Competitive scenario
      • 6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.6. Norway
      • 6.3.6.1. Key country dynamics
      • 6.3.6.2. Regulatory framework
      • 6.3.6.3. Competitive scenario
      • 6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.7. Sweden
      • 6.3.7.1. Key country dynamics
      • 6.3.7.2. Regulatory framework
      • 6.3.7.3. Competitive scenario
      • 6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key country dynamics
      • 6.3.8.2. Regulatory framework
      • 6.3.8.3. Competitive scenario
      • 6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. India
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Mexico
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Kaneka Eurogentec S.A
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. LGC Biosearch Technologies
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Biolegio
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Twist Bioscience
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global oligonucleotide synthesis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 5 North America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 7 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 9 Canada oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 12 Europe oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 14 Germany oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 15 UK oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 16 UK oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 17 France oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 18 France oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 19 Italy oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 20 Italy oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 21 Spain oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 22 Spain oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 23 Denmark oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 24 Denmark oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 25 Sweden oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 26 Sweden oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 27 Norway oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 28 Norway oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 32 China oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 33 China oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 34 Japan oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 35 Japan oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 36 India oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 37 India oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 38 South Korea oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 39 South Korea oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 40 Australia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 41 Australia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 42 Thailand oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 43 Thailand oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 44 Latin America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 46 Latin America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 47 Brazil oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 48 Brazil oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 49 Mexico oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 50 Mexico oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 51 Argentina oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 52 Argentina oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 55 MEA oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Africa oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 57 South Africa oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 60 UAE oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 61 UAE oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 62 Kuwait oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 63 Kuwait oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide synthesis market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Synthetic biology market value, 2023 (USD billion)
  • Fig. 16 Market trends & outlook
  • Fig. 17 Top investors in drug R&D as a percentage of net sales (2019)
  • Fig. 18 PESTEL analysis
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 Oligonucleotide synthesis market: Product & service outlook & key takeaways
  • Fig. 21 Oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 22 Oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Short RNA oligos (<65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Long RNA oligos (>65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 CRISPR (sgRNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Equipment/synthesizer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 50 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 200 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 100 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Oligonucleotide synthesis market: Application outlook & key takeaways
  • Fig. 53 Oligonucleotide synthesis market: Application movement analysis
  • Fig. 54 PCR primers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 PCR assays and panels market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 DNA microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Fluorescence In Situ Hybridization (FISH) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Antisense oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030, (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. key country dynamics
  • Fig. 65 U.S. oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Canada key country dynamics
  • Fig. 67 Canada oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Europe oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 UK key country dynamics
  • Fig. 70 UK oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Germany key country dynamics
  • Fig. 72 Germany oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 France key country dynamics
  • Fig. 74 France oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Spain key country dynamics
  • Fig. 76 Spain oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Italy key country dynamics
  • Fig. 78 Italy oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark key country dynamics
  • Fig. 80 Denmark oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Sweden key country dynamics
  • Fig. 82 Sweden oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Norway key country dynamics
  • Fig. 84 Norway oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Asia Pacific oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Japan key country dynamics
  • Fig. 87 Japan oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 China key country dynamics
  • Fig. 89 China oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 India key country dynamics
  • Fig. 91 India oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Australia Key country dynamics
  • Fig. 93 Australia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Thailand key country dynamics
  • Fig. 95 Thailand oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea key country dynamics
  • Fig. 97 South Korea oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Brazil key country dynamics
  • Fig. 100 Brazil oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Mexico key country dynamics
  • Fig. 102 Mexico oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Argentina key country dynamics
  • Fig. 104 Argentina oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 MEA oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa key country dynamics
  • Fig. 107 South Africa oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia key country dynamics
  • Fig. 109 Saudi Arabia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 UAE key country dynamics
  • Fig. 111 UAE oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait key country dynamics
  • Fig. 113 Kuwait oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Market participant categorization
  • Fig. 115 Global oligonucleotide synthesis market position analysis, 2023
  • Fig. 116 Strategic framework